Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.

about

Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.

Item

http://www.wikidata.org/entity/Q51010554

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Once-weekly dulaglutide 1.5 mg ...... intravenous glucose infusion.

@en

Once-weekly dulaglutide 1.5 mg ...... intravenous glucose infusion.

@nl

type

Item

label

Once-weekly dulaglutide 1.5 mg ...... intravenous glucose infusion.

@en

Once-weekly dulaglutide 1.5 mg ...... intravenous glucose infusion.

@nl

prefLabel

Once-weekly dulaglutide 1.5 mg ...... intravenous glucose infusion.

@en

Once-weekly dulaglutide 1.5 mg ...... intravenous glucose infusion.

@nl

P1476

Once-weekly dulaglutide 1.5 mg ...... intravenous glucose infusion.

@en

P2093

Amparo de la Peña

http://www.w3.org/2001/XMLSchema#string

Christoph Kapitza

http://www.w3.org/2001/XMLSchema#string

Corina Loghin

http://www.w3.org/2001/XMLSchema#string

Ronan P Kelly

http://www.w3.org/2001/XMLSchema#string

Xin Zhang

http://www.w3.org/2001/XMLSchema#string

Xuewei Cui

http://www.w3.org/2001/XMLSchema#string

P2860

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

Acute and steady-state insulin responses to glucose in nonobese diabetic subjects

The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.

Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology.

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

The gastrointestinal tract and glucose tolerance.

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.

P304

517-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12847

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27976833

http://www.w3.org/2001/XMLSchema#string